Coverage window: August 10-16, 2026
The strongest material this week came from trial records rather than polished clinical readouts. That still matters when the records are specific: they show which cell products are entering patients, how invasive the delivery is, what comparator exists, and how long safety will be watched.
The theme is placement. Cells are being delivered into the cochlea, brain, subretinal space, intrathecal compartment, or bloodstream. Those routes carry very different scientific questions and patient burdens, so the route matters almost as much as the cell type.
1. Rincell-1 moves auditory-neuron replacement into a cochlear-implant trial
Primary sources:
- https://clinicaltrials.gov/study/NCT07032038
- https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/r1-25-the-first-in-human-trial-of-rincell-1/
- https://www.rinri-therapeutics.com/uk-mhra-approval-received-for-first-in-human-trial-of-rincell-1-a-first-in-class-regenerative-cell-therapy-for-sensorineural-hearing-loss/
Rinri Therapeutics' Rincell-1 record was updated on August 11. ClinicalTrials.gov lists a not-yet-recruiting Phase 1/2 randomized open-label trial in 20 adults with neural hearing loss who are eligible for cochlear implantation.
The design compares cochlear implantation alone with cochlear implantation plus Rincell-1, an otic neural progenitor cell therapy. The primary outcome is frequency and severity of adverse events through 52 weeks. The UK Health Research Authority summary adds two details that make the trial more than a device add-on: treated participants receive low-dose immunosuppression for ten months, and they are expected to enter long-term follow-up through ten years after surgery.
Why it matters: hearing-loss cell therapy rarely sits beside Parkinson, stroke, and retina in regenerative-neuro coverage, but this trial belongs in the same conversation. It asks whether a neural progenitor product can be delivered during an established surgical workflow and followed with both safety monitoring and auditory-neural measures.
Full analysis: Rincell-1 Brings Cell Replacement Into a Cochlear-Implant Trial
2. B2065 adds a placebo-controlled adipose-MSC study in acute ischemic stroke
Primary source: https://clinicaltrials.gov/study/NCT07371624
Tasly Pharmaceutical Group updated its B2065 acute ischemic stroke study on August 13. The record describes a recruiting Phase 1/2a trial of allogeneic adipose-derived mesenchymal stromal cell injection in 54 participants.
The design is randomized, double-blind, and placebo-controlled. The primary outcomes are safety-focused: dose-limiting toxicities within 28 days, infusion-related reactions, and all-cause mortality at several follow-up points reaching 24 months. The study also asks which dose may carry preliminary efficacy, but the public record is still a trial-design update, not a result.
Why it matters: acute-stroke MSC programs are easy to over-read when the wording jumps straight to recovery. This record is more concrete. It puts route, comparator, dose, and safety follow-up on the page, which is the minimum structure needed before any later functional claim can be judged.
Full analysis: What B2065 Has to Prove After MultiStem
3. The earlier NR1 chronic-stroke study is active, not recruiting
Primary sources:
- https://clinicaltrials.gov/study/NCT04631406
- https://www.cirm.ca.gov/clinical-trial/safety-and-tolerability-study-of-neural-stem-cells-nr1-in-subjects-with-chronic-ischemic-subcortical-stroke/
Clarion Cells' NR1 study was updated on August 12. ClinicalTrials.gov lists it as an active, not recruiting Phase 1/2a study of intracerebral neural stem cells in chronic ischemic subcortical stroke, with estimated enrollment of 27 participants.
The primary outcomes are treatment-emergent adverse events and Fugl-Meyer motor score over 0-12 months. CIRM's trial page describes the cells as neural stem cells derived from human embryonic stem cells and frames the study around motor disability after chronic ischemic stroke.
Why it matters: this is the earlier safety and tolerability layer behind a chronic-stroke neural-cell program that is now moving into more controlled designs. It keeps the patient burden visible: direct brain delivery, motor follow-up, and the need to understand safety before treating any motor-score change as durable benefit.
4. Two RPE replacement records keep retina in the early-clinical lane
Primary sources:
- https://clinicaltrials.gov/study/NCT04339764
- https://clinicaltrials.gov/study/NCT07594236
- https://www.cirm.ca.gov/clinical-trial/autologous-ipsc-derived-retinal-pigment-epithelium-cell-therapy-to-restore-vision-in-blinding-eye-disease/
Two retinal cell-therapy records moved on August 10. The National Eye Institute's autologous iPSC-derived RPE/PLGA transplantation study for geographic atrophy is listed as a recruiting Phase 1/2 trial with 20 estimated participants. The primary outcomes are adverse events and visual-acuity change at 12 months.
Cellio Therapeutics' C.001 record is also listed as recruiting. It is a Phase 1 open-label dose-escalation study in retinal pigment epithelium-mediated maculopathy, including geographic atrophy and Stargardt disease, with 15 estimated participants and a primary safety window of 3 months after subretinal injection. CIRM lists the Cellio program as an autologous iPSC-derived retinal pigment epithelium cell therapy for age-related macular degeneration.
Why it matters: retina remains one of the cleanest places to learn from cell replacement in humans because anatomy, graft location, imaging, and visual measures can be followed more directly than in most brain targets. These are still small safety-first programs, but they show how much of the field is moving through the eye before broader CNS claims become realistic.
5. A seven-child cerebral palsy MSC pilot puts intrathecal safety first
Primary source: https://clinicaltrials.gov/study/NCT07763028
Gadjah Mada University posted and updated a Phase 1 cerebral palsy study on August 13. The record lists an open-label, single-arm pilot of one intrathecal administration of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in children with cerebral palsy.
The study is small: seven actual participants. Its primary outcomes are whether participants successfully complete intrathecal administration and 6-month follow-up, and whether treatment-emergent adverse events occur during that period.
Why it matters: pediatric cerebral palsy is a setting where public claims can outrun the study design very quickly. This record is appropriately modest: route feasibility and short-term safety after intrathecal MSC delivery, not proof of neurological recovery.
6. MASTERS-2 is now listed as terminated
Primary sources:
- https://clinicaltrials.gov/study/NCT03545607
- https://jamanetwork.com/journals/jamaneurology/fullarticle/2813591
The MASTERS-2 record for MultiStem in acute ischemic stroke was updated on August 11 and is now listed as terminated. ClinicalTrials.gov describes the study as a Phase 3 randomized, quadruple-masked, placebo-controlled trial with 206 actual participants and modified Rankin Scale shift analysis at 90 days as the primary outcome.
The registry record itself does not explain the termination. The public context is that the earlier TREASURE randomized trial in Japan, published in JAMA Neurology in 2024, reported that intravenous MultiStem was safe but did not improve short-term 90-day outcomes compared with placebo.
Why it matters: this belongs next to the newer stroke-cell records, not as a simple negative headline but as a reminder of the bar. Stroke gives cell therapy a serious clinical need, but it also gives the field difficult timing, heterogeneous injury, high background care effects, and endpoints that punish loose assumptions.
7. The iDReAM ALS study is completed in the registry
Primary sources:
- https://clinicaltrials.gov/study/NCT04744532
- https://www.cira.kyoto-u.ac.jp/e/pressrelease/news/240718-100000.html
Kyoto University's iPSC-based Drug Repurposing for ALS Medicine study was updated on August 10 and is now listed as completed. The ClinicalTrials.gov record describes a Phase 1/2 bosutinib study in ALS with 46 actual participants.
This is not a cell-transplant program. Its place in this issue is the path that led to the trial: Kyoto/CiRA describes bosutinib as a candidate identified through ALS patient-specific iPS cell-derived brain-cell assays, followed by Phase 1 and Phase 2 investigator-initiated clinical work.
Why it matters: iPSC platforms do not have to become transplant products to matter clinically. Sometimes the more practical route is disease modeling, candidate selection, and drug repurposing. The registry completion makes this a good moment to watch for the full clinical dataset and what Kyoto decides to do next.